A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union’s Perspectives
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The problem of drug shortages has been reported worldwide, gaining prominence in multiple domains and several countries in recent years. The aim of the study was to analyze, characterise and assess this problem in Belgium and France, while also adopting a wider perspective from the European Union. A qualitative methodological approach was employed, including semi-structured interviews with the representatives of respective national health authorities, pharmaceutical companies and wholesalers, as well as hospital and community pharmacists. The research was conducted in early 2014. Four themes, which were identified through the interviews, were addressed in the paper, i.e. a) defining drug shortages, b) their dynamics and perception, c) their determinants, d) the role of the European and national institutions in coping with the problem. Three groups of determinants of drug shortages were identified throughout this study: manufacturing problems, distribution and supply problems, and problems related to economic aspects. Currently, the Member States of the European Union are striving to resolve the problem very much on their own, although a far more focused and dedicated collaboration may well prove instrumental in coping with drug shortages throughout Europe more effectively. To the best of the authors' knowledge, this is the first qualitative study to investigate the characteristics, key determinants, and the problem drivers of drug shortages, focusing on this particular group of countries, while also adopting the European Union's perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qualitative research in health care: Analysing qualitative data
Pope, C. (2000) · BMJ · doi:10.1136/bmj.320.7227.114 · Cited by 8,131
Gibbs, G. (2007) · doi:10.4135/9781849208574 · Cited by 4,299
ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems
Fox, E. R., Birt, A., James, K. B., Kokko, H., Salverson, S., & Soflin, D. L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090026 · Cited by 217
Shortages of medicines: a complex global challenge
Gray, A., & Manasse, H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.101303 · Cited by 136 · cited 3×
“antibiotics and oncologic medicines [1,5,10,48].”
Background
Cited by
Drug Shortage: Causes, Impact, and Mitigation Strategies
Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A. H., Omer, S., Hu, S., Babar, Z.-U.-D., Fang, Y., & Yang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693426 · Cited by 322
Medicine Shortages: Gaps Between Countries and Global Perspectives
Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00763 · Cited by 147
Self-citationBochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00942 · Cited by 112
“We identified and addressed four major themes: (a) defining drug shortages, (b) their dynamics and perception, (c) their determinants, and (d) the role of the European and national institutions in coping with the problem (Bogaert et al., 2015).”
BackgroundSelf-citationYang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., & Fang, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165183 · Cited by 70
Medicine shortages in Fiji: A qualitative exploration of stakeholders’ views
Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., & Moles, R. J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178429 · Cited by 57
Heiskanen, K., Ahonen, R., Kanerva, R., Karttunen, P., & Timonen, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179479 · Cited by 51
“This may be due to the fact that the pharmaceutical industry’s operating costs have grown significantly in the past ten years and the industry has become more reluctant to market medicines [21].”
Background
Metadata
- Authors
- Bogaert, P., Bochenek, T., Prokop, A., & Pilc, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-05
- Volume
- 10
- Issue
- 5
- Pages
- e0125691
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2105458859
- Cited by
- 89
- References
- 4
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.